ROP drug granted orphan designation

Article

Iplex (mecasermin rinfabate), a complex of recombinant human insulin-like growth factor-I (rhIGF-I) and its predominant binding protein IGFBP-3 (rhIGFBP-3) developed for the treatment of retinopathy of prematurity (ROP), has been granted orphan drug designation by the EMEA, according to a statement from Iplex developers Insmed Inc and Premacure AB.

Iplex (mecasermin rinfabate), a complex of recombinant human insulin-like growth factor-I (rhIGF-I) and its predominant binding protein IGFBP-3 (rhIGFBP-3) developed for the treatment of retinopathy of prematurity (ROP), has been granted orphan drug designation by the EMEA, according to a statement from Iplex developers Insmed Inc and Premacure AB.

The orphan designation entitles Premacure to assistance and reduced fees for pre- and post-authorization activities.

Iplex is currently approved in the US for the treatment of growth failure in children. Premacure intends to launch a multicentre Phase II trial of Iplex in the ROP indication during the second quarter of this year, and to continue investigating the drug for other indications.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Related Content
An image of two medical professionals in medical scrubs standing and talking in a medical facility. Concept image for surgery, consultant and resident ophthalmologists, immediate sequential bilateral cataract surgery, outcomes for ISBCS and eye care. Image credit: ©Rawpixel.com – stock.adobe.com

Resident and consultant ophthalmologists compare immediate sequential bilateral cataract surgery successes

Lynda Charters
June 12th 2025
Article

A new study compared results to determine a more comprehensive understanding of the relationship between the grade of surgeon and ISBCS outcomes

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

An older man with glasses sits in a wheelchair. Concept image for cabozantinib and corneal perforation, ocular adverse effects, vascular endothelial growth factor VEGF tyrosine kinase inhibitor TKI. Image credit: ©Photographee.eu – stock.adobe.com

Case report examines corneal perforation associated with tyrosine kinase inhibitor

Lynda Charters
June 10th 2025
Article

Cabozantinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, has previously been associated with hepatic and dermatologic adverse effects

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

Marc Labetoulle, MD, PhD, and the logo for the European Society of Ophthalmology (SOE) meeting in Lisbon, Portugal, 7 to 9 June, 2025. Concept image for SOE presentation, poster presentation on dry eye research. Includes the email soe.2025@soevision.org

New dry eye disease study compares two preservative-free artificial tear drops

Hattie Hayes;Marc Labetoulle, MD, PhD
June 7th 2025
Article

Research findings from the multicentre clinical study were presented at the European Society of Ophthalmology (SOE) meeting in Lisbon, Portugal

The Belém Tower (Torre de Belém) in Lisbon, Portugal. Concept image for ophthalmology conference, European Society of Ophthalmology SOE Congress 2025 meeting program and schedule. Image credit: ©PhotosbyPatrick – stock.adobe.com

Keynote lectures and YO sessions at the 2025 SOE Congress

Hattie Hayes
June 7th 2025
Article

Special programming for young ophthalmologists will be hosted in the YO lounge

© 2025 MJH Life Sciences

All rights reserved.